Innovent Biologics announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has awarded Breakthrough Therapy Designation (BTD) for olverembatinib. This designation recognises it as a potential promising treatment for patients diagnosed with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST) who have undergone first-line therapy. Olverembatinib is a novel third-generation BCR-ABL inhibitor that has received approval in China for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukaemia (CML-CP) or accelerated-phase CML (CML-AP) that harbour the T315I mutation. Olverembatinib, an orally active third-generation BCR-ABL inhibitor has shown efficacy in targeting a range of BCR-ABL mutants, including the challenging T315I mutation commonly encountered in CML. By offering a therapeutic option for patients with these resistant forms of CML, olverembatinib represents a significant advancement in the field of leukaemia treatment.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!